Autobacteriographic studies of clarithromycin and erythromycin in mice
Open Access
- 1 April 1990
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 34 (4) , 562-567
- https://doi.org/10.1128/aac.34.4.562
Abstract
The antimicrobial activity of clarithromycin was compared with that of erythromycin in experimentally infected mice by whole-body autobacteriography. In mice with systemic staphylococcal infections, the number of vital microbes in the body was relatively low in the early period after oral administration of erythromycin, but increased thereafter to the levels found in nonmedicated control mice. On the other hand, with clarithromycin treatment, a significantly smaller number of microbes was evident throughout the body. The microbes were scarcely seen in the parenchyma of any organs during the examination period. This potent antimicrobial activity of clarithromycin compared with that of erythromycin was further demonstrated in mice with respiratory infections. On the other hand, to examine the distribution properties of both antibiotics in the whole body, an autoradiographic study was carried out with [N-methyl-14C]clarithromycin and [N-methyl-14C]erythromycin. Both labeled antibiotics were distributed widely throughout the body after oral administration in both uninfected control mice and mice with systemic infections. However, the radioactivity was more marked and persistent for [14C]clarithromycin than it was for [14C]erythromycin, particularly in the lungs. The observations described above indicate the superior in vivo antimicrobial activity of clarithromycin compared with that of erythromycin and suggest that the superiority of clarithromycin is largely attributed to its favorable distribution properties. The advantages of whole-body autobacteriography, coupled with whole-body autoradiography, are discussed.This publication has 15 references indexed in Scilit:
- Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in ratsAntimicrobial Agents and Chemotherapy, 1989
- In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1987
- In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatisAntimicrobial Agents and Chemotherapy, 1987
- Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1987
- In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatisAntimicrobial Agents and Chemotherapy, 1987
- In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolideAntimicrobial Agents and Chemotherapy, 1986
- Experimental Pseudomonas Pneumonia Model in Normal miceKansenshogaku Zasshi, 1986
- Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A.The Journal of Antibiotics, 1984
- Erythromycin VI: Kinetics of Acid-Catalyzed Hydrolysis of Erythromycin Oxime and ErythromycylamineJournal of Pharmaceutical Sciences, 1978
- N-DIDEMETHYL-N-PROPIONYL-6,9-9,12-ERYTHROMYCIN A-SPIROKETAL, A NEW METABOLITE OF ERYTHROMYCIN ETHYL SUCCINATE IN MAN1978